Cardioxyl Raises Series B Led By OrbiMed

By Angela Sormani — 3 years ago

Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.

Continue